ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company is headquartered in San Diego, California.
| Revenue (TTM) | $1.10B |
| Gross Profit (TTM) | $674.45M |
| EBITDA | $92.71M |
| Operating Margin | -1.72% |
| Return on Equity | 37.30% |
| Return on Assets | 3.69% |
| Revenue/Share (TTM) | $6.47 |
| Book Value | $7.29 |
| Price-to-Book | 3.48 |
| Price-to-Sales (TTM) | 4.07 |
| EV/Revenue | 3.239 |
| EV/EBITDA | 38.26 |
| Quarterly Earnings Growth (YoY) | -81.80% |
| Quarterly Revenue Growth (YoY) | 9.70% |
| Shares Outstanding | $171.24M |
| Float | $127.19M |
| % Insiders | 0.32% |
| % Institutions | 98.93% |
Volatility is currently contracting
Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Harmony Biosciences, Acadia, Biogen, Insmed and Agios show positive Earnings ESPs ahead of Q2 results, setting up closely watched earnings reports.
The mean of analysts' price targets for Acadia (ACAD) points to a 30.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
ACAD wins FDA's Fast Track status for remlifanserin in Alzheimer's disease psychosis as its phase II data readout approaches and phase III enrollment advances.
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report second quarter 2026 financial results on Tuesday, August 4, 2026, after the close of the U.S. financial markets. Acadia's management team will also host a conference call and webcast on August 4, 2026, at 4:30 p.m. Eastern Time. The conference call will be available on Acadia's website, acadia.com under the investors section and will be archived for approximately 90 days. The conference ca.
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Royalty Pharma (RPRX) and Acadia Pharmaceuticals (ACAD). But which of these two companies is the best option for those looking for undervalued stocks?
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Carl Segerstrom as Chief People Officer, effective July 6. Carl will lead the company's global people and culture strategy, supporting its next phase of growth as a leading neurological and rare disease company focused on advancing therapies for patients with significant unmet needs. He will serve as a member of Acadia's executive leadership team. “Carl is a proven global leader with a stro.
Acadia stock jumps 7% as CHMP backs Daybu for EU approval in Rett syndrome, with the European Commission set to make a final decision in the coming months.
Acadia Pharmaceuticals demonstrates steady commercial growth with Nuplazid and Daybue, supported by a recent positive CHMP opinion for Daybue in Europe. Remlifanserin's upcoming phase 2 readout in Alzheimer's disease psychosis is a high-risk, high-reward catalyst not priced into ACAD's current valuation. I maintain a bullish outlook on ACAD based on commercial products Nuplazid and Daybue, but above-average returns depend on pipeline or business development success.
Acadia (ACAD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ACAD and any ticker you trade — then tracks every position and per-strategy win rate.
